Riskpilot← Back to searchSign inGet full accessDNASENSE ApS
APSActiveCVR 36036869Niels Jernes Vej 10Research and experimental development on natural sciences and engineering · NACE 7210Est. 201414 employeesdnasense.dk
Revenue 2025
DKK 7,9M
+36% vs 2024
EBITDA margin
28.6%
+1299% vs 2024
Equity ratio
15.8%
Financial strength
Net profit 2025
DKK 895K
+1655% vs 2024
| Revenue | DKK 7,9M | +36% |
| EBITDA | DKK 2,3M | +1299% |
| Net profit | DKK 895K | +1655% |
| Total assets | DKK 10,4M | +227% |
| Equity | DKK 1,6M | +120% |
| Employees | 14 | — |
Legal name
DNASENSE ApS
CVR number
36036869
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
3. juli 2014
Share capital
DKK 50.000
Employees
14 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er konsulent- og analysearbejde inden for DNA sekventering og mikrobiologi og hermed efter ledelsens skøn beslægtet virksomhed.
Address
Niels Jernes Vej 10
Phone
+4522932191
Email
info@dnasense.dk
Website
dnasense.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.124 | 1.796 | 2.296 | 3.380 | 1.446 | 3.040 | 4.258 | 4.533 | 5.841 | 7.915 |
| Staff expenses | -0 | -662 | -925 | -1.620 | -2.502 | -2.814 | -2.914 | -3.127 | -3.681 | -5.679 | -5.651 |
| EBITDA | 529 | 462 | 871 | 676 | 878 | -1.368 | 126 | 1.132 | 852 | 162 | 2.264 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -61 | -145 | -918 |
| EBIT | 529 | 462 | 871 | 676 | 878 | -1.368 | 126 | 1.132 | 791 | 16 | 1.346 |
| Net financials | -0 | -2 | -4 | -4 | -7 | -14 | -24 | -18 | -26 | -89 | -166 |
| Profit before tax | 529 | 460 | 868 | 672 | 871 | -1.382 | 102 | 1.114 | 765 | -73 | 1.181 |
| Tax | 125 | 101 | 195 | 148 | 192 | -301 | 24 | 247 | 215 | -15 | 286 |
| Net profit | 404 | 359 | 673 | 524 | 679 | -1.082 | 78 | 867 | 550 | -58 | 895 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 684 | 877 | 1.185 | 1.597 | 2.073 | 871 | 1.231 | 2.836 | 2.219 | 3.175 | 10.378 |
| Equity | 454 | 513 | 886 | 910 | 1.289 | -93 | -15 | 852 | 802 | 744 | 1.639 |
| Long-term debt | 0 | 0 | 0 | 109 | 148 | 0 | 419 | 281 | 369 | 309 | 3.635 |
| Short-term debt | 231 | 365 | 299 | 578 | 636 | 964 | 827 | 1.702 | 1.035 | 2.122 | 5.059 |
| Total debt | 231 | 365 | 299 | 687 | 784 | 964 | 1.246 | 1.983 | 1.404 | 2.431 | 8.694 |
EBITDA margin
28.6%
This company
15.8%
Market median
+81% vs market
20152025
Equity ratio
15.8%
This company
38.2%
Market median
-59% vs market
20152025
Return on equity
54.6%
This company
18.4%
Market median
+197% vs market
20152025
Net profit margin
11.3%
This company
8.1%
Market median
+40% vs market
20152025
Asset turnover
0.76×
This company
1.12×
Market median
-32% vs market
20152025
Debt / equity
5.33×
This company
0.62×
Market median
-760% vs market
20152025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-03 – 2015-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MT Management | Management | 2020 | — | — |
MA Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Clinical-Microbiomics A/S | Company | 100.0% | 100.0% | 2024 |
Lukassen Holding ApS | Company | 10.0% | 10.0% | 2021 |
MTSondergaard Holding ApS | Company | 10.0% | 10.0% | 2021 |
Kjeldal Investments ApS | Company | 10.0% | 10.0% | 2021 |
RWO Holding ApS | Company | 10.0% | 10.0% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MANJIN ApS
DNASENSE ApS Board members of DNASENSE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mads Toft Søndergaard | Management | 0 companies |
| Mads Albertsen | Management | 0 companies |
| Henrik Bjørn Nielsen | Board of Directors | 0 companies |
| Anders Christian Neto de Sousa Grøn | Chairman | 0 companies |
| Henrik Knudsen | Board of Directors | 0 companies |
| Manoj Nirmal Dadlani | Board of Directors | 0 companies |
| Anders Mohr Christensen | Board of Directors | 0 companies |